By David Doolittle
Originally published by our sister publication, Pharmacy Practice News
The FDA approved tebentafusp-tebn (Kimmtrak, Immunocore), a bispecific T-cell engager designed to redirect the immune system to recognize and kill cancerous cells, for the treatment of adults with unresectable or metastatic uveal melanoma.